BR112018014016A2 - combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer - Google Patents

combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer

Info

Publication number
BR112018014016A2
BR112018014016A2 BR112018014016A BR112018014016A BR112018014016A2 BR 112018014016 A2 BR112018014016 A2 BR 112018014016A2 BR 112018014016 A BR112018014016 A BR 112018014016A BR 112018014016 A BR112018014016 A BR 112018014016A BR 112018014016 A2 BR112018014016 A2 BR 112018014016A2
Authority
BR
Brazil
Prior art keywords
agonist
combination
monoclonal antibody
cancer treatment
antibody agonist
Prior art date
Application number
BR112018014016A
Other languages
English (en)
Inventor
David Thall Aron
Long Hua
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112018014016A2 publication Critical patent/BR112018014016A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a terapias de combinação compreendendo um agonista de ox40 e um agonista de 4-1bb e a utilização das terapias de combinação para o tratamento de câncer.
BR112018014016A 2016-01-25 2017-01-17 combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer BR112018014016A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662286616P 2016-01-25 2016-01-25
PCT/IB2017/050244 WO2017130076A1 (en) 2016-01-25 2017-01-17 Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer

Publications (1)

Publication Number Publication Date
BR112018014016A2 true BR112018014016A2 (pt) 2019-02-05

Family

ID=57956335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014016A BR112018014016A2 (pt) 2016-01-25 2017-01-17 combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer

Country Status (12)

Country Link
US (1) US20190031765A1 (pt)
EP (1) EP3408294A1 (pt)
JP (1) JP6783312B2 (pt)
KR (2) KR20210013777A (pt)
CN (1) CN108473587A (pt)
AU (2) AU2017211540B2 (pt)
BR (1) BR112018014016A2 (pt)
CA (1) CA2955184A1 (pt)
HK (1) HK1259253A1 (pt)
MX (1) MX2018008995A (pt)
RU (1) RU2748949C2 (pt)
WO (1) WO2017130076A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA3059366A1 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
NZ760841A (en) 2017-07-11 2024-02-23 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111936507B (zh) * 2018-03-23 2022-11-01 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
CN110357961B (zh) * 2018-04-10 2022-08-23 无锡智康弘义生物科技有限公司 抗人4-1bb单克隆抗体及其制备方法和用途
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
EP3958908A1 (en) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin antibody-drug conjugates and uses thereof
CA3141452A1 (en) * 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
MX2022003633A (es) 2019-09-25 2022-04-19 Pfizer Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2021141977A1 (en) 2020-01-07 2021-07-15 Board Of Regents, The University Of Texas System Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
KR20230013125A (ko) * 2020-06-30 2023-01-26 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 4-1bb 결합 단백질 및 이의 용도
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在***或癌症中的应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
WO2022250502A1 (en) * 2021-05-27 2022-12-01 Yuhan Corporation Ox40 agonist and use thereof
WO2023036041A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗4-1bb的激动型抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
WO2006055697A2 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
EP1896030A1 (en) 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
PT2851374T (pt) * 2007-12-14 2017-06-20 Pfizer Moléculas de ligação ao recetor humano ox40
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
EP2726275B1 (en) 2011-06-30 2019-12-04 Compagnie Générale des Etablissements Michelin Method and apparatus for installing a tread ring upon a tire carcass
WO2013119202A1 (en) 2012-02-06 2013-08-15 Providence Health & Services - Oregon Cancer treatment and monitoring methods using ox40 agonists
CN106102774A (zh) 2013-12-17 2016-11-09 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
KR20170004006A (ko) * 2014-05-21 2017-01-10 화이자 인코포레이티드 암을 치료하기 위한 항-ｃｃｒ4 항체 및 4-1ｂｂ 효능제의 조합
EP3310810A1 (en) * 2015-06-16 2018-04-25 Merck Patent GmbH Pd-l1 antagonist combination treatments

Also Published As

Publication number Publication date
HK1259253A1 (zh) 2019-11-29
JP2019506403A (ja) 2019-03-07
AU2020210145A1 (en) 2020-08-13
RU2748949C2 (ru) 2021-06-02
KR20180103150A (ko) 2018-09-18
KR20210013777A (ko) 2021-02-05
CA2955184A1 (en) 2017-07-25
MX2018008995A (es) 2019-01-10
US20190031765A1 (en) 2019-01-31
AU2017211540A1 (en) 2018-07-19
AU2017211540B2 (en) 2020-04-30
WO2017130076A1 (en) 2017-08-03
EP3408294A1 (en) 2018-12-05
RU2018127164A3 (pt) 2020-02-28
CN108473587A (zh) 2018-08-31
RU2018127164A (ru) 2020-02-28
JP6783312B2 (ja) 2020-11-11

Similar Documents

Publication Publication Date Title
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
HK1257730A1 (zh) 抗despr單克隆抗體用於癌症和中風的靶向療法及成像
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
GT201700286A (es) Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
EA201691974A1 (ru) Антитела против ox40 и способы их применения
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
GT201700284A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
DK3500299T3 (da) Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
BR112017012381A2 (pt) imunoterapia para doença angiogênica
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2757 DE 07-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.